FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154028722> ?p ?o ?g. }

• W2154028722 endingPage "1349" @default.
• W2154028722 startingPage "1340" @default.
• W2154028722 abstract "Abstract There are quantitative and/or qualitative mechanisms allowing androgen receptor (AR) growth signaling in androgen ablation refractory prostate cancer cells. Regardless of the mechanism, agents that deplete AR protein expression prevent such AR growth signaling. Thapsigargin (TG) is a highly cell-penetrant sequiterpene-lactone that once inside cells inhibits (IC50, ∼10 nmol/L) critically important housekeeping SERCA 2b calcium pumps in the endoplasmic reticulum. Using a series of five genetically diverse androgen ablation refractory human prostate cancer lines (LNCaP, LAPC-4, VCaP, MDA-PCa-2b, and CWR22Rv1), TG inhibition of SERCA pumps consistently results in depletion of the endoplasmic reticulum Ca+2 coupled with μmol/L elevation in the intracellular free Ca+2 initiating a molecular cascade that: (a) inhibits Cap-dependent AR protein synthesis resulting in 90% depletion of AR protein by 24 hours of TG exposure, (b) arrests the cells in G0, and (c) induces their apoptotic death. Unfortunately, due to its highly lipophilic nature, TG is not deliverable as a systemic agent without host toxicity. Therefore, TG analogues containing amino acids were developed, which retain ability to deplete AR protein and induce cell death and which can be covalently linked to peptide carriers producing water soluble prodrugs for systemic delivery. Specific amino acid sequences are used to restrict the liberation of cytotoxic amino acid containing TG analogues from the peptide prodrug by prostate-specific proteases, such as prostate-specific antigen and prostate-specific membrane antigen, or cancer-specific proteases, such as fibroblast activation protein, so that toxicity of these prodrugs is selectively targeted to metastatic sites of prostate cancer. Based on these results, these prodrugs are undergoing clinical development. [Mol Cancer Ther 2008;8(5):1340–9]" @default.
• W2154028722 created "2016-06-24" @default.
• W2154028722 creator A5001771354 @default.
• W2154028722 creator A5009560029 @default.
• W2154028722 creator A5023762654 @default.
• W2154028722 creator A5042550448 @default.
• W2154028722 creator A5043265453 @default.
• W2154028722 creator A5066312474 @default.
• W2154028722 creator A5067845778 @default.
• W2154028722 date "2009-05-01" @default.
• W2154028722 modified "2023-10-02" @default.
• W2154028722 title "Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells" @default.
• W2154028722 cites W1577630176 @default.
• W2154028722 cites W1964741914 @default.
• W2154028722 cites W1966704219 @default.
• W2154028722 cites W1977710819 @default.
• W2154028722 cites W1985412375 @default.
• W2154028722 cites W1992475843 @default.
• W2154028722 cites W1996325724 @default.
• W2154028722 cites W2002599993 @default.
• W2154028722 cites W2003955264 @default.
• W2154028722 cites W2015710917 @default.
• W2154028722 cites W2018188180 @default.
• W2154028722 cites W2021051883 @default.
• W2154028722 cites W2022635468 @default.
• W2154028722 cites W2023097049 @default.
• W2154028722 cites W2024432096 @default.
• W2154028722 cites W2033961707 @default.
• W2154028722 cites W2043029683 @default.
• W2154028722 cites W2043103956 @default.
• W2154028722 cites W2043340288 @default.
• W2154028722 cites W2049372779 @default.
• W2154028722 cites W2060196770 @default.
• W2154028722 cites W2063535351 @default.
• W2154028722 cites W2070348954 @default.
• W2154028722 cites W2074497307 @default.
• W2154028722 cites W2078400569 @default.
• W2154028722 cites W2079688281 @default.
• W2154028722 cites W2079944569 @default.
• W2154028722 cites W2081197593 @default.
• W2154028722 cites W2085847636 @default.
• W2154028722 cites W2088154205 @default.
• W2154028722 cites W2100987153 @default.
• W2154028722 cites W2112918122 @default.
• W2154028722 cites W2116263669 @default.
• W2154028722 cites W2118055719 @default.
• W2154028722 cites W2141569270 @default.
• W2154028722 cites W2141571283 @default.
• W2154028722 cites W2144498681 @default.
• W2154028722 cites W2144941480 @default.
• W2154028722 cites W2150609534 @default.
• W2154028722 cites W2151151062 @default.
• W2154028722 cites W2163148645 @default.
• W2154028722 cites W2166264553 @default.
• W2154028722 doi "https://doi.org/10.1158/1535-7163.mct-08-1136" @default.
• W2154028722 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3383025" @default.
• W2154028722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19417145" @default.
• W2154028722 hasPublicationYear "2009" @default.
• W2154028722 type Work @default.
• W2154028722 sameAs 2154028722 @default.
• W2154028722 citedByCount "37" @default.
• W2154028722 countsByYear W21540287222012 @default.
• W2154028722 countsByYear W21540287222013 @default.
• W2154028722 countsByYear W21540287222014 @default.
• W2154028722 countsByYear W21540287222015 @default.
• W2154028722 countsByYear W21540287222016 @default.
• W2154028722 countsByYear W21540287222017 @default.
• W2154028722 countsByYear W21540287222018 @default.
• W2154028722 countsByYear W21540287222019 @default.
• W2154028722 countsByYear W21540287222020 @default.
• W2154028722 countsByYear W21540287222021 @default.
• W2154028722 countsByYear W21540287222022 @default.
• W2154028722 countsByYear W21540287222023 @default.
• W2154028722 crossrefType "journal-article" @default.
• W2154028722 hasAuthorship W2154028722A5001771354 @default.
• W2154028722 hasAuthorship W2154028722A5009560029 @default.
• W2154028722 hasAuthorship W2154028722A5023762654 @default.
• W2154028722 hasAuthorship W2154028722A5042550448 @default.
• W2154028722 hasAuthorship W2154028722A5043265453 @default.
• W2154028722 hasAuthorship W2154028722A5066312474 @default.
• W2154028722 hasAuthorship W2154028722A5067845778 @default.
• W2154028722 hasBestOaLocation W21540287221 @default.
• W2154028722 hasConcept C121608353 @default.
• W2154028722 hasConcept C126322002 @default.
• W2154028722 hasConcept C158617107 @default.
• W2154028722 hasConcept C181199279 @default.
• W2154028722 hasConcept C182220744 @default.
• W2154028722 hasConcept C185592680 @default.
• W2154028722 hasConcept C2777146706 @default.
• W2154028722 hasConcept C2779723316 @default.
• W2154028722 hasConcept C2780192828 @default.
• W2154028722 hasConcept C502942594 @default.
• W2154028722 hasConcept C55493867 @default.
• W2154028722 hasConcept C61367390 @default.
• W2154028722 hasConcept C71924100 @default.
• W2154028722 hasConcept C86803240 @default.
• W2154028722 hasConcept C96232424 @default.
• W2154028722 hasConceptScore W2154028722C121608353 @default.

• next